Adage Capital Partners GP L.L.C. Sells 5,561,111 Shares of Veru Inc. (NASDAQ:VERU)

Adage Capital Partners GP L.L.C. decreased its position in Veru Inc. (NASDAQ:VERU - Free Report) by 70.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,300,000 shares of the company's stock after selling 5,561,111 shares during the quarter. Adage Capital Partners GP L.L.C. owned approximately 1.57% of Veru worth $1,496,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in VERU. State Street Corp grew its stake in Veru by 4.3% in the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company's stock valued at $1,593,000 after purchasing an additional 84,483 shares during the period. Jane Street Group LLC raised its position in Veru by 142.8% in the third quarter. Jane Street Group LLC now owns 96,454 shares of the company's stock worth $74,000 after acquiring an additional 56,736 shares during the period. Barclays PLC boosted its stake in Veru by 309.2% in the third quarter. Barclays PLC now owns 184,777 shares of the company's stock valued at $142,000 after acquiring an additional 139,617 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Veru by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company's stock worth $2,261,000 after purchasing an additional 131,720 shares during the last quarter. Finally, PVG Asset Management Corp lifted its stake in Veru by 13.1% in the third quarter. PVG Asset Management Corp now owns 636,970 shares of the company's stock valued at $490,000 after purchasing an additional 73,815 shares during the last quarter. Hedge funds and other institutional investors own 47.16% of the company's stock.

Veru Stock Performance

NASDAQ:VERU traded down $0.01 during trading hours on Monday, reaching $0.50. The stock had a trading volume of 417,766 shares, compared to its average volume of 1,765,762. The stock has a market cap of $73.34 million, a P/E ratio of -1.93 and a beta of -0.69. The stock has a 50 day simple moving average of $0.53 and a 200 day simple moving average of $0.64. Veru Inc. has a 12-month low of $0.45 and a 12-month high of $1.75.

Veru (NASDAQ:VERU - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. On average, equities analysts expect that Veru Inc. will post -0.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Michael L. Rankowitz purchased 95,279 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was purchased at an average cost of $0.55 per share, with a total value of $52,403.45. Following the completion of the acquisition, the director now directly owns 195,279 shares of the company's stock, valued at approximately $107,403.45. The trade was a 95.28 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 14.90% of the stock is owned by insiders.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.